127 related articles for article (PubMed ID: 33281191)
1. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse.
Ciceri S; Montalvão-de-Azevedo R; Tajbakhsh A; Bertolotti A; Spagnuolo RD; Boschetti L; Capasso M; D'Angelo P; Serra A; Diomedi-Camassei F; Meli M; Nantron M; Quarello P; Buccoliero AM; Tamburini A; Ciniselli CM; Verderio P; Collini P; Radice P; Spreafico F; Perotti D
Cancer Gene Ther; 2021 Sep; 28(9):1016-1024. PubMed ID: 33281191
[TBL] [Abstract][Full Text] [Related]
2. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.
Walz AL; Ooms A; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Bowlby R; Brooks D; Ma Y; Mungall AJ; Moore RA; Schein J; Marra MA; Huff V; Dome JS; Chi YY; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Jafari N; Ross N; Gastier-Foster JM; Perlman EJ
Cancer Cell; 2015 Feb; 27(2):286-97. PubMed ID: 25670082
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.
Wegert J; Ishaque N; Vardapour R; Geörg C; Gu Z; Bieg M; Ziegler B; Bausenwein S; Nourkami N; Ludwig N; Keller A; Grimm C; Kneitz S; Williams RD; Chagtai T; Pritchard-Jones K; van Sluis P; Volckmann R; Koster J; Versteeg R; Acha T; O'Sullivan MJ; Bode PK; Niggli F; Tytgat GA; van Tinteren H; van den Heuvel-Eibrink MM; Meese E; Vokuhl C; Leuschner I; Graf N; Eils R; Pfister SM; Kool M; Gessler M
Cancer Cell; 2015 Feb; 27(2):298-311. PubMed ID: 25670083
[TBL] [Abstract][Full Text] [Related]
5. Altered binding affinity of SIX1-Q177R correlates with enhanced WNT5A and WNT pathway effector expression in Wilms tumor.
Stevenson MJ; Phanor SK; Patel U; Gisselbrecht SS; Bulyk ML; O'Brien LL
Dis Model Mech; 2023 Nov; 16(11):. PubMed ID: 37815464
[TBL] [Abstract][Full Text] [Related]
6. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
[TBL] [Abstract][Full Text] [Related]
7. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition.
Li CM; Guo M; Borczuk A; Powell CA; Wei M; Thaker HM; Friedman R; Klein U; Tycko B
Am J Pathol; 2002 Jun; 160(6):2181-90. PubMed ID: 12057921
[TBL] [Abstract][Full Text] [Related]
8. SIX1 protein expression selectively identifies blastemal elements in Wilms tumor.
Sehic D; Karlsson J; Sandstedt B; Gisselsson D
Pediatr Blood Cancer; 2012 Jul; 59(1):62-8. PubMed ID: 22180226
[TBL] [Abstract][Full Text] [Related]
9. Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour.
Torrezan GT; Ferreira EN; Nakahata AM; Barros BD; Castro MT; Correa BR; Krepischi AC; Olivieri EH; Cunha IW; Tabori U; Grundy PE; Costa CM; de Camargo B; Galante PA; Carraro DM
Nat Commun; 2014 Jun; 5():4039. PubMed ID: 24909261
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers.
Imam JS; Buddavarapu K; Lee-Chang JS; Ganapathy S; Camosy C; Chen Y; Rao MK
Oncogene; 2010 Sep; 29(35):4971-9. PubMed ID: 20603620
[TBL] [Abstract][Full Text] [Related]
11. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
Gadd S; Huff V; Walz AL; Ooms AHAG; Armstrong AE; Gerhard DS; Smith MA; Auvil JMG; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Hermida LC; Davidsen T; Gesuwan P; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Dome JS; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Ross N; Gastier-Foster JM; Arold ST; Perlman EJ
Nat Genet; 2017 Oct; 49(10):1487-1494. PubMed ID: 28825729
[TBL] [Abstract][Full Text] [Related]
12. Loss or oncogenic mutation of DROSHA impairs kidney development and function, but is not sufficient for Wilms tumor formation.
Kruber P; Angay O; Winkler A; Bösl MR; Kneitz S; Heinze KG; Gessler M
Int J Cancer; 2019 Mar; 144(6):1391-1400. PubMed ID: 30367465
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CITED1, SIX1, and CD56 protein expression for identification of blastemal elements in Wilms tumor.
Sehic D; Ciornei CD; Gisselsson D
Am J Clin Pathol; 2014 Jun; 141(6):828-33. PubMed ID: 24838327
[TBL] [Abstract][Full Text] [Related]
14. Assessment of promoter methylation and expression of SIX2 as a diagnostic and prognostic biomarker in Wilms' tumor.
Song D; Yue L; Wu G; Ma S; Guo L; Yang H; Liu Q; Zhang D; Xia Z; Wang L; Zhang J; Zhao W; Guo F; Wang J
Tumour Biol; 2015 Sep; 36(10):7591-8. PubMed ID: 25921281
[TBL] [Abstract][Full Text] [Related]
15. In Silico Analyses Reveal the Relationship Between SIX1/EYA1 Mutations and Conotruncal Heart Defects.
Li B; Xu L; Hong N; Chen S; Xu R
Pediatr Cardiol; 2018 Jan; 39(1):176-182. PubMed ID: 29043394
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic analyses guided by high resolution whole-genome SNP array reveals a possible role of
Ciceri S; Gamba B; Corbetta P; Mondini P; Terenziani M; Catania S; Nantron M; Bianchi M; D'Angelo P; Torri F; Macciardi F; Collini P; Di Martino M; Melchionda F; Di Cataldo A; Spreafico F; Radice P; Perotti D;
Oncotarget; 2018 Sep; 9(75):34079-34089. PubMed ID: 30344923
[TBL] [Abstract][Full Text] [Related]
17. Population-based risk estimates of Wilms tumor in sporadic aniridia. A comprehensive mutation screening procedure of PAX6 identifies 80% of mutations in aniridia.
Grønskov K; Olsen JH; Sand A; Pedersen W; Carlsen N; Bak Jylling AM; Lyngbye T; Brøndum-Nielsen K; Rosenberg T
Hum Genet; 2001 Jul; 109(1):11-8. PubMed ID: 11479730
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
19. microRNA-188 is downregulated in oral squamous cell carcinoma and inhibits proliferation and invasion by targeting SIX1.
Wang L; Liu H
Tumour Biol; 2016 Mar; 37(3):4105-13. PubMed ID: 26490981
[TBL] [Abstract][Full Text] [Related]
20. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer.
Smith AL; Iwanaga R; Drasin DJ; Micalizzi DS; Vartuli RL; Tan AC; Ford HL
Oncogene; 2012 Dec; 31(50):5162-71. PubMed ID: 22286770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
